April 19, 2017 - Orgenesis, Inc. (NASDAQ:ORGS) has filed a financial statement reporting Assets of $33,487,000 USD. Previously, on April 16, 2018, Orgenesis, Inc. reported Assets of $39,872,000 USD. This represents a change of -16.01% in Assets.

Period EndPeriodValue
2016-11-30 2016-Q4 33,487,000
2017-11-30 2017-Q4 39,872,000
2016-02-29 2016-Q1 36,200
2015-08-31 2015-Q3 35,550,517
2015-05-31 2015-Q2 34,583,806
2015-02-28 2015-Q1 1,226,577
2014-08-31 2014-Q3 1,660,105
2014-05-31 2014-Q2 154,333
2014-02-28 2014-Q1 293,361
2013-08-31 2013-Q3 599,627
2013-05-31 2013-Q2 1,133,235
2013-02-28 2013-Q1 97,830
2012-08-31 2012-Q3 349,865
2012-05-31 2012-Q2 181,547
2012-02-29 2012-Q1 353,794
2016-05-31 2016-Q2 36,746
2016-08-31 2016-Q3 36,555
2015-11-30 2015-Q4 38,748
2014-11-30 2014-Q4 2,249,000
2013-11-30 2013-Q4 114,221
2012-11-30 2012-Q4 48,167
2011-11-30 2011-Q4 2,340
2010-11-30 2010-Q4 1,617
2017-02-28 2017-Q1 36,272,000
2017-05-31 2017-Q2 36,267,000
2017-08-31 2017-Q3 37,422,000
2018-02-28 2018-Q1 42,411,000
CostOfRevenue DeferredRevenueCurrent GeneralAndAdministrativeExpense IncomeTaxExpenseBenefit IncreaseDecreaseInDeferredRevenue IncreaseDecreaseInPrepaidExpense InterestExpenseShortTermBorrowings OtherNonoperatingIncomeExpense PrepaidExpenseCurrent ResearchAndDevelopmentExpense Revenues ScheduleOfFinancialExpensesZeroThreeEightFourZeroZeroMbrFourRynTkMKW ScheduleOfFinancialExpensesZeroThreeEightFourZeroZeroNKyFourtrSbNEightcT ScheduleOfFinancialExpensesZeroThreeEightFourZeroZeroOnenFivedvBmbCPZerob ScheduleOfFinancialExpensesZeroThreeEightFourZeroZeroQJEightQHEightvKrPTQ ScheduleOfFinancialExpensesZeroThreeEightFourZeroZeroSixVScnTyThreeEightTNX ScheduleOfFinancialExpensesZeroThreeEightFourZeroZeroSrrhxFiveEightxbQlSeven ScheduleOfFinancialExpensesZeroThreeEightFourZeroZeroTHSevenFkNTWyFourCJ ScheduleOfFinancialExpensesZeroThreeEightFourZeroZeroTwoFivefSixggwbHLHk ScheduleOfFinancialExpensesZeroThreeEightFourZeroZeroVpvvmTwoFiveHMcck ScheduleOfFinancialExpensesZeroThreeEightFourZeroZeroZpQmcvvcRzmFour ScheduleOfFinancialExpensesZeroThreeEightFourZeroZerohdRbGVtSixGOneWh ScheduleOfFinancialExpensesZeroThreeEightFourZeroZerozHFouryNxKThreeFFourGb ScheduleOfIntangibleAssetsFutureAmortizationExpenseZeroThreeEightFourZeroZeroFourGqHKpPHOnevrG ScheduleOfIntangibleAssetsFutureAmortizationExpenseZeroThreeEightFourZeroZerobTsKmSevenvVKScB ScheduleOfResearchAndDevelopmentExpensesZeroThreeEightFourZeroZeroFourLMfQFcMBTXZero ScheduleOfResearchAndDevelopmentExpensesZeroThreeEightFourZeroZeroddPFTwolPmTSixHN ScheduleOfResearchAndDevelopmentExpensesZeroThreeEightFourZeroZerofpdTgJEightdrKRS ScheduleOfResearchAndDevelopmentExpensesZeroThreeEightFourZeroZerolDpQDOneTZeroFMTwoNine ScheduleOfResearchAndDevelopmentExpensesZeroThreeEightFourZeroZeroshmKPlBDJbtFour ScheduleOfResearchAndDevelopmentExpensesZeroThreeEightFourZeroZerovGLmQlmNSixZerokT ScheduleOfResearchAndDevelopmentExpensesZeroThreeEightFourZeroZeroxZtEighttqXtPlFV ScheduleOfRevenueZeroThreeEightFourZeroZeroEightNineXwREightzvFiveThreeTd ScheduleOfRevenueZeroThreeEightFourZeroZeroEightwpCFourTwomFFourhgEight ScheduleOfRevenueZeroThreeEightFourZeroZeroKcwVnhZeroNzMtFour ScheduleOfRevenueZeroThreeEightFourZeroZerotttPFiveZRhCOneJr ScheduleOfRevenueZeroThreeEightFourZeroZeroyfmEightcBSMkcgFive ScheduleOfRevenueZeroThreeEightFourZeroZerozMThreeSixFkqmgSsR ScheduleOfRevenuesFromMajorCustomersZeroThreeEightFourZeroZeroTJtWLZNZClFk ScheduleOfRevenuesFromMajorCustomersZeroThreeEightFourZeroZeroTSevenMKgxCThreeWFourDFour ScheduleOfRevenuesFromMajorCustomersZeroThreeEightFourZeroZeroTwoNNinexFivegWDTRsl ScheduleOfRevenuesFromMajorCustomersZeroThreeEightFourZeroZeroXlsBMSevenvEightOnenrM ScheduleOfRevenuesFromMajorCustomersZeroThreeEightFourZeroZerofKFivexOneFiveybTfps ScheduleOfRevenuesFromMajorCustomersZeroThreeEightFourZeroZeroxTwoNqFourrgKbJFourThree StockBasedCompensationExpensesRelatedToOptionsGrantedToEmployeesAndDirectors

Related News Stories

Orgenesis, Inc. - Overlooked Stock In The Gene Therapy Contract Development With R&D Pipeline

2018-06-03 seekingalpha
Overlooked specialty contract development and manufacturing stock in the exciting field of advanced cell therapy with a potential for an exponential upside. (184-3)

CUSIP: 68619K105